



THE **2<sup>ND</sup>**  
SOHO  
ISRAEL  
MEETING

THE **8<sup>TH</sup>**  
INTERNATIONAL  
DAVIDOFF  
CONFERENCE

STATE OF THE ART AND NEXT QUESTIONS

# Program & Speakers book

# Program



## Scientific Program

# THURSDAY, MAY 23<sup>RD</sup> 2024

ANU - Museum of the Jewish People, Tel Aviv

**08:00-09:00** Registration, Gathering & Exhibition

**09:00-09:20** Opening Remarks

**Hagop Kantarjian, MD**, *Chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center*

**Lena Koren, MD**, *Director of the Beilinson Campus & Deputy Director of the Rabin Medical Center, Israel*

**Karen Avraham, PhD**, *Dean of the Faculty of Medicine & Health Sciences, Tel-Aviv University*

**Nati Horowitz, MD**, *Chairman, Israel Society of Hematology and Blood Transfusions, Israel*

**Gal Markel, MD**, *Head, Davidoff Cancer Center, Rabin Medical Center, Israel*

**Pia Raanani, MD**, *Head, Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Israel*

**09:20-10:55** Session 1 - Acute Leukemia

**Chairpersons - Yishai Ofran, MD | Galia Stemer, MD**

09:20-09:40 AML 2024: New Classifications, New Targets

**Richard Stone, MD**, *Dana Farber Institute, Boston, USA*

09:40-09:55 Incorporation of Targeted and Immune-Based Therapies in Frontline ALL therapy

**Hagop Kantarjian, MD**, *University of Texas MD Anderson Cancer Center, Houston, USA*

- 09:55-10:10 Updates in Post-Remission Maintenance for AML  
**Gail Roboz, MD**, *Weill Cornell Medicine, The New York Presbyterian Hospital, New York, USA*
- 10:10-10:25 Ph +Positive ALL  
**Robin Foa, MD**, *'La Sapienza' University of Rome, Italy*
- 10:25-10:40 An update on venetoclax-based regimens for newly diagnosed AML  
**Courtney DiNardo, MD**, *University of Texas MD Anderson Cancer Center, Houston, USA*
- 10:40-10:55 **Panel Discussion**

**10:55-11:25 Coffee Break & Exhibition**

**11:25-12:40 Session 2 - Chronic Lymphocytic Leukemia**

**Chairpersons - Yair Harishanu, MD | Nadav Sarid, MD**

- 11:25-11:45 CLL Therapy: Time-Limited or Continuous Therapy?  
The Debate Continuous  
**Jan Burger, MD**, *University of Texas MD Anderson Cancer Center, Houston, USA*
- 11:45-12:00 Evolving Frontline Therapy of CLL  
**Nitin Jain, MD**, *University of Texas MD Anderson Cancer Center, Houston, USA*
- 12:00-12:15 CLL 2024: Standards and Open Questions  
**Barbara Eichhorst, MD**, *University Hospital of Cologne, Germany*
- 12:15-12:30 Novel Treatments on the Horizon for CLL  
**William (Bill) Wierda, MD**, *University of Texas MD Anderson Cancer Center, Houston, USA*
- 12:30-12:40 **Panel Discussion**

**12:40-13:40 Lunch & Exhibition**



### 13:40-15:25 Session 3 - Chronic Myeloid Leukemia & Myeloproliferative Disorders

**Chairpersons: Pia Raanani, MD | Ariel Aviv, MD**

- 13:40-14:00 Treatment Free Remission in CML: Where we Stand?  
**Delphine Rea, MD**, *Hopital Saint-Louis, Paris, France*
- 14:00-14:15 Updates on Myeloproliferative Neoplasms  
**Lucia Masarova, MD**, *University of Texas MD Anderson Cancer Center, Houston, USA*
- 14:15-14:35 New CML Lab Recommendations for Diagnosis and Monitoring  
**Simona Soverini, PhD**, *Alma Mater Studiorum Universita di Bologna, Italy*
- 14:35-14:55 Survival, Causes of Death and Perspectives of TFR in CML Patients: Data from the Italian Campus Registry  
**Giuseppe Saglio, MD**, *University of Turin, Italy*
- 14:55-15:10 Re-Assessing Some Established Treatment Practices in CML  
**Hagop Kantarjian, MD**, *University of Texas MD Anderson Cancer Center, Houston, USA*
- 15:10-15:25 **Panel Discussion**

### 15:25-15:45 Coffee Break & Exhibition

#### 15:45-16:05 Special Debate:

CLL - Time Limited Treatment or Treatment Until Progression

**Moderator: Jennifer Brown, MD**, *Dana-Farber Cancer Institute (DFCI), Boston, USA*

**Debaters: Tamar Tadmor, MD**, *Division of Hematology and Blood Bank, Bnai Zion Medical Center, Haifa, Israel* & **Gilad Itchaki, MD**, *Hematology, Meir Medical Center, Israel*

**16:05-17:50****Session 4 - Lymphoproliferative Disorders & Plasma Cell Dyscrasias****Chairpersons: Ronit Gurion, MD | Yael Cohen, MD**

16:05-16:20

Approach to Newly Diagnosed Multiple Myeloma  
**Morie Gertz, MD**, *Mayo Clinic Rochester Minnesota, USA*

16:20-16:35

Future Directions in Treatment of Hodgkin Lymphoma  
**Alison Moskowitz, MD**, *Memorial Sloan Kettering Cancer Center, NY, USA*

16:35-16:50

Divide and Conquer: Evolving Approaches to the Upfront Treatment of Systemic T cell Lymphomas  
**Steve Horwitz, MD**, *Memorial Sloan Kettering Cancer Center NY, USA*

16:50-17:05

Diagnosing and Treating Plasma Cell Dyscrasias in 2024  
**Krina Patel, MD**, *University of Texas MD Anderson Cancer Center, Houston, USA*

17:05-17:20

Updates on Novel Therapies for T cell Lymphoma  
**Swaminathan Padmanabhan Iyer, MD**, *University of Texas MD Anderson Cancer Center, Houston, USA*

17:20-17:35

CAR T-Cell Therapy for B-cell Lymphomas, Progress Made and Future Directions  
**Loretta Nastoupil, MD**, *University of Texas MD Anderson Cancer Center, Houston, USA*

17:35-17:50

Next Questions in Follicular Lymphoma  
**Gilles Salles, MD**, *Memorial Sloan Kettering Cancer Center NY, USA*

17:50-18:00

**Closing Remarks**

# FRIDAY, MAY 24<sup>TH</sup> 2024

Port Tower Hotel, Tel Aviv

**09:00-12:00**

## Round Tables

09:00-10:00

### **Chronic Myeloid Leukemia**

**Delphine Rea, MD; Giuseppe Saglio, MD;  
Simona Soverini, PhD; Adi Shacham-Abulafia, MD**

10:00-11:00

### **Acute Leukemia**

**Richard Stone, MD; Ofir Wolach, MD**

Short Break

11:00-12:00

### **Chronic Lymphocytic Leukemia**

**Jan Burger, MD; Tamar Tadmor, MD;  
Gilad Itchaki, MD; Barbara Eichhorst, MD**

# Speakers



## Dr. Pia Raanani

---

Prof. Pia Raanani MD is Head of the Division of Hematology at the Rabin Medical Center. She is Clinical Full Professor in Hematology at the Tel-Aviv University.



Prof. Raanani trained in hematology at the Sheba Medical Center and completed a fellowship in CML at the Hammersmith Hospital, Royal Postgraduate Medical School in London. In 2007 she established the Hemato-oncology Hospitalization Unit at the Davidoff Cancer Center. Prof. Raanani was Head of the Department of Hematology of the Faculty of Medicine Tel-Aviv University between 2010-2014 and has been Head of the Research Funds Committee of the Sackler School of Medicine since 2014.

Prof. Raanani is on the Editorial board of several international hematology journals. Since 2015 she has served as Ambassador for Israel of the MD Anderson Society of Hematologic Oncology (SOHO).

Since July 2017 she is Editor-in-Chief of the journal Acta Haematologica.

Prof. Raanani is a co-author of 235 articles as well as chapters in books. During the last years, she has chaired several international scientific meetings in the field of hemato-oncology.

## Dr. Hagop Kantarjian

---

Hagop Kantarjian, M.D. is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he is also the Samsung Distinguished Leukemia Chair in Cancer Medicine. He is also a non-resident fellow in health policy at the Rice University Baker Institute.



Doctor Kantarjian has received several prestigious honours and awards including the 37th Jeffrey A Gottlieb Memorial Award (2012), the John Mendelsohn Lifetime Scientific Achievement Award (2008), the Joseph H. Burchenal Memorial Award (2013), the Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer (2014), and America's Top Doctors, Castle Connolly Medical (2003-present). He was also selected the top Castle Connolly National Physician of the Year Award for Lifetime Achievement (2014).

Doctor Kantarjian's research focuses on translational-clinical developmental therapeutics in leukemia. In the past four decades, he has made several contributions that improved prognosis and survival in patients with chronic myeloid leukemia (tyrosine kinase inhibitors, e.g. imatinib, dasatinib, nilotinib, bosutinib which improved the 10-year survival from 20% to 90%), in acute lymphocytic leukemia (HPER-CVAD regimen and its derivatives which improved cure rates from 20% to 60+%), the discovery of decitabine for the treatment of myelodysplastic syndrome, and of clofarabine for the treatment of leukemias, among others.

His research and collaborations were the basis for the FDA approvals of over 25 drugs in leukemia. He is an author on over 2,200 peer-reviewed publications.



## Dr. Barbara Eichhorst

---

Barbara Eichhorst graduated at the Medical school of the University of Munich and wrote her doctoral thesis in the field of hematology evaluating signalling transduction pathways in Hodgkin cells.



Dr Eichhorst finished her internship at the department III for internal medicine at Klinikum Großhadern of the University of Munich and specialized in internal medicine. Since February 2005 she works at the Department I for Internal Medicine and cancer center at the University hospital of Cologne and finished her specialisation in hematology and internal oncology. She is assistant professor and consultant since December 2012 and adjunct professor of the University of Cologne since July 2019.

Her main focus of interest is chronic lymphocytic leukemia (CLL). As leading group member of the German CLL Study Group (GCLLSG) she was and is principal investigator in several phase II and III trials evaluating treatment optimization in CLL.

Since 2005 she is secretary of the GCLLSG (head Prof. Dr. Michael Hallek). Publishing many papers in the field of CLL treatment within clinical trials Barbara Eichhorst is a world-wide known specialist for CLL. She is also a member of many national and international organizations including the European Haematology association and American Society of Hematology and was elected as member of International Workshop of CLL (iwCLL) in 2019.

## Dr. Krina Patel

---



Dr Krina K. Patel is an associate professor in the Department of Lymphoma and Myeloma, Division of Cancer Medicine, and was previously in the Department of Stem Cell Transplantation, at the University of Texas MD Anderson Cancer Center (UT MDACC) in Houston Texas.

She earned her bachelor's degree at the University of Pennsylvania, medical degree from the University of Texas Southwestern Medical Center, Dallas and completed a fellowship in hematology-oncology at UT MDACC where she served as Chief fellow for 2 years and completed her Master of Science in the lab of Laurence Cooper MD PHD evaluating the combination of NY-ESO-1 T-APC vaccine with TCR in Multiple Myeloma cell line and mouse models. She currently serves as Service Line Leader for her department.

Dr Patel's research focus is on improving therapy and outcomes for patients with MM and other plasma cell dyscrasias. Her specific research interests include improving survival and quality of life for patients with MM, POEMS, and plasmablastic lymphoma, using cellular therapy such as chimeric antigen receptor T cells with or without transplant and combining immunotherapy in the induction, transplant, maintenance, and salvage settings. She has acted as principal investigator on several MM clinical trials with a focus on immunotherapies such as novel CAR T, monoclonal antibodies, cytokines, and vaccine studies. She is also currently co-PI for a translational study evaluating ctDNA and scRNAseq data for patients undergoing standard of care CAR T studies. Outside of her clinical and translational interests, Dr. Patel is dedicated to improving outcomes and access to these novel therapies for vulnerable patient populations such as minority patient groups and those with high risk disease.

Dr Patel is a member of ASH, ASCO, ASGCT, AACR, and ASTCT. Her research has been published in numerous peer-reviewed journals.

## Dr. Jan Burger

---

Jan A. Burger, M.D., Ph.D. is a Professor of Medicine at the MD Anderson Cancer Center in Houston, USA.



Dr. Burger received his M.D./Ph.D. degree at Albert-Ludwigs-University in Freiburg, Germany, with subsequent clinical training and board certification in Internal Medicine and Hematology/Oncology at Freiburg University Hospital, before moving to MD Anderson in 2005. In 2006, Dr. Burger received the “*Venia legendi*” (Habilitation) for Internal Medicine at Albert-Ludwigs-University in Freiburg. Moreover, from 1996 to 1999, Dr. Burger received postdoctoral research training in Hematology and Immunology at the University of California, San Diego.

As a clinical and laboratory investigator, Dr. Burger focuses on developing new therapeutic approaches for targeting the microenvironment in chronic lymphocytic leukemia (CLL), other B cell malignancies, and acute leukemias. Laboratory research by Dr. Burger’s group characterized B cell receptor (BCR)-associated kinases, such as BTK and PI3 kinases, as therapeutic targets.

Dr. Burger serves as a principal investigator on clinical trials which explore these targets in CLL, and has been leading key trials that supported the approval of the BTK inhibitor ibrutinib (Resonate 2: ibrutinib for CLL frontline therapy). For his innovative research, Dr. Burger received several awards, among them, the Arthur Pappenheim Award by the DGHO, a Kimmel Scholar Award, ASCO Young Investigator and Career Development awards, the Leukemia and Lymphoma Society Scholar award, and the MD Anderson Faculty Scholar Award.

Dr. Burger is a regular speaker at EHA and ASH, and has published in the leading Journals in his field.

## Dr. Delphine Rea

---

Dr Delphine Rea is appointed at Saint-Louis University Hospital, Paris, France, where she works as a physician in the Department of Hematology.



Her main clinical and research interest focuses on malignant myeloid disorders. She is responsible for the Chronic Myeloid Leukemia clinical care and research program. She has been the principal investigator or investigator of many academic- or industry-sponsored clinical trials dedicated to CML, including pivotal studies that have led to the approval of tyrosine kinase inhibitors or treatment-free remission studies.

She belongs to the board of directors of the French cooperative group of CML (Fi-LMC), contributes to the CML project of the European LeukemiaNet, to the organization committee of European School of Haematology (ESH) iCMLf annual conference, to the Society of Hematologic Oncology (SOHO) annual meeting education committee and to the scientific advisory board of iCMLf.

## Dr. Morie Gertz

---

Dr. Gertz is the Roland Seidler Jr. Professor of the Art of Medicine and Chair Emeritus of the Department of Internal Medicine, at Mayo Clinic in Rochester, Minnesota. He is a Master of the American College of Physicians.



Undergraduate degree was awarded with highest distinction from Northwestern University graduating Phi Beta Kappa. Dr. Gertz received his medical degree cum laude from Loyola Medical School in Maywood, Illinois and was elected to Alpha Omega Alpha the medical honor society. He completed a 3-year medical residency at Rush Presbyterian St. Luke's Hospital in Chicago, Illinois, and was voted Resident of the Year for 2 of those years. He completed training in hematology and oncology at Mayo.

He was awarded the Mayo Distinguished Clinician Award for his contributions to patient care. He served 1 year term as president of the Mayo clinic staff officers and counselors.


He has served as chair of the division of Hematology and chair of the department of Medicine at Mayo Clinic Rochester.

He was the first treasurer of the International Society of Amyloidosis and International Myeloma Society. He has authored over 1000 peer reviewed publications and over 90 book chapters. He serves on the editorial boards of Amyloidosis, Acta Haematologica and Clinical Lymphoma & Myeloma. He is coeditor of Neoplastic Diseases of the Blood. In 2019 The Department of Medicine awarded him its lifetime research achievement award. In 2024 he became chair of the Hematology Board for the American Board of Internal Medicine.

## Dr. Gilles Salles

---

Gilles Salles, MD, PhD, was appointed Chief of the Lymphoma Service at MSK in 2020. He previously held the position of Professor of Hematology and Medicine at the University of Lyon and Head of the Department of Hematology at the Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, in Pierre-Bénite, France.



Dr. Salles obtained his medical degree and his doctoral degree in differentiation, genetics, and immunology from the Université Claude Bernard Lyon-1. He completed further training as a researcher in oncology at the Dana-Farber Cancer Institute of Harvard Medical School.

Throughout his career, Dr. Salles has been especially interested in the clinical and biological study of lymphoma. The primary focus of his work is on the description and validation of prognostic factors and clinical trials in indolent lymphomas. His team has also examined several aspects of lymphoma biology, including T-cell and B-cell lymphoma models, signaling, and genomic biology of indolent lymphomas.

Dr. Salles has been involved in the investigation and development of new therapeutic agents such as targeted therapies, new monoclonal antibodies, and other immunotherapies in the field. He has led large international studies evaluating treatment options in patients with follicular lymphoma.

A member of several international societies, including the American Society of Hematology, Dr. Salles is also the author of more than 600 publications, including articles in international peer-reviewed journals such as *The New England Journal of Medicine*, *Blood*, *The Journal of Clinical Oncology*, *The Lancet*, *Haematologica*, *Lancet Oncology*, and *Leukemia and Lymphoma*.



## Dr. Robin Foa

---

Emeritus Professor of Hematology, 'Sapienza' University of Rome. He earned his medical degree in Turin, Italy, and specialized in pediatrics and hematology. Worked at the MRC Leukaemia Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London between 1976 and 1979. Sabbatical at Memorial Sloan-Kettering Cancer Center, New York, between 1991 and 1992.




He is part of the European LeukemiaNet (ELN) Steering Committee and referee for national and international funding agencies. Chairman of the Scientific Committee of the 4th EHA Congress, Barcelona 1999, councilor of EHA until December 2002, and member of the Education Committee of EHA until December 2005. President-Elect, President and Past-President of EHA during the years 2007-2013. Chairman Education Committee and Outreach Unit of EHA up to June 2017. Member of EHA's Global Outreach Committee.

Has authored over 850 papers, reviews and books. Has been co-editor of *Leukemia and Lymphoma*, and associate editor of the *British Journal of Hematology* and of *The Hematology Journal*. Editor-in-chief of *The Hematology Journal* up to December 2004 and of *Haematologica* from January 2005 to February 2008.

## Dr. Richard Stone

---

Richard Stone, MD, is the Chief of Staff at Dana-Farber Cancer Institute (DFCI). He is also Director of Translational Research for the Leukemia Division in the Department of Medical Oncology at DFCI, and Professor of Medicine at Harvard Medical School. Dr. Stone is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies including acute leukemia, myeloproliferative disorders and myelodysplastic syndrome [MDS] (a bone marrow failure state that may convert to leukemia).



In addition to his work at Dana-Farber, Dr. Stone serves as Chairman of the Leukemia Committee for the national cooperative trials group, Alliance. He is a Vice Chair of the National Comprehensive Cancer Network (NCCN) MDS panel and is also a member of the NCCN AML panel. He previously served as the Chair of the Medical Advisory Board of the Aplastic Anemia and MDS International Foundation, the Chair of the ABIM Oncology Board, and has served on the editorial boards of Leukemia Research, Blood and Journal of Clinical Oncology.

Dr. Stone has participated extensively in teaching medical students, residents, and fellows, as well as graduate medical education courses on leukemia and related disorders. He is the author of many academic papers that have been published in the New England Journal of Medicine, Blood, Leukemia as well as numerous other journals. He had a significant leadership role in the development of five new drugs for the treatment of acute myeloid leukemia (AML) that were approved in the past two years. He is the Co-Principle Investigator of the SPORE in Myeloid Malignancies at Dana-Farber/Harvard Cancer Center.

Dr. Stone earned his medical degree from Harvard Medical School in 1981. He completed his internal medicine residency training and served as Chief Medical Resident at Brigham and Women's Hospital. He completed his hematology-oncology fellowship at Dana-Farber.

## **Dr. Giuseppe Saglio**

---

Giuseppe Saglio is Emeritus Professor of Haematology and Internal Medicine at the University of Turin. Professor Saglio has been coordinator of the PhD programme in Medicine and Experimental Therapy of the University of Turin and Director of the Department of Clinical and Biological Sciences of the same University.



He has published more than 600 peer-reviewed articles in the fields of molecular pathogenesis of haematological diseases, molecularly targeted therapy and molecular characterization of haematological malignancies.

In 2017 Prof Saglio was nominated Knight of the Italian Republic for scientific merits and for his long lasting service for the Italian University.

## **Dr. Simona Soverini**

---

Simona Soverini is Associate Professor of Hematology at the Department of Medical and Surgical Sciences of the University of Bologna and head of the Myeloid Leukemia Research group at the Institute of Hematology “Lorenzo e Ariosto Seragnoli” at the S. Orsola University Hospital in Bologna, Italy.



She obtained her MSc in Molecular Biology and her PhD in Clinical and Experimental Haematology from the University of Bologna.

Her research focuses on chronic myeloid leukemia and systemic mastocytosis. Professor Soverini is author of over 180 publications in peer-reviewed journals, with a h-index of 53.

She is a reviewer for a number of international journals, including Blood, Leukemia, Haematologica, Clinical Cancer Research and British Journal of Haematology, and sits in the Editorial Boards of Journal of Hematology & Oncology, Frontiers in Oncology and International Journal of Molecular Sciences.

She is a member of the board of Directors of the Italian Society of Experimental Hematology (SIES) and a member of the European Hematology Association (EHA), the American Society of Hematology (ASH) and the Society of Hematological Oncology (SOHO). She has served on the Scientific Program Committees for EHA and SOHO congresses.

## Dr. Swaminathan Iyer

---

Dr. Swaminathan Iyer, MD is a Professor of Medicine at University of Texas, MD Anderson Cancer Center Houston, TX as a Lymphoma specialist. Prof. Swami iyer is an internationally recognized expert in clinical trials for cancer with two FDA approvals, in lymphoma and leukemia. He graduated from Bangalore Medical College, Rajiv Gandhi University of Health Sciences with a Gold Medal in Pathology in 1994. His post-graduation includes training at AIIMS, Wayne State University and University of Miami and is a American Board of Internal Medicine (ABIM) Diplomate in Internal Medicine and Hematology.



In addition, he has a laboratory interest in aptamers, chimeric antigen receptor Therapies (CAR-Ts), and machine learning approaches to predict biomarkers from whole slide images. At the University of Texas MD Anderson, he leads the T cell lymphoma (TCL) program. This involves collaboration with a multidisciplinary team in several research areas, including clinical trials with novel agents and cellular therapies, epidemiology, risk factors, and new risk prediction models. The rarity of the disease requires collaborative efforts to translate treatment advances. As the largest consortium of its kind, it could remove preventable roadblocks to collect and evaluate each TCL subtype, improve sample collection for genomic testing, and enroll more patients in clinical trials. Furthermore, it will accelerate the enrollment of newer therapies, including histone deacetylase inhibitors, EZH1/2 inhibitors, PI3K inhibitors, Syk inhibitors, immune checkpoint inhibitors, CD47 blockers, and cellular therapies for TCL.

Dr.Iyer serves as the President of the Indo American Cancer Association with the goal of giving back service and care for cancer patients in India. He is the recipient of several awards including American Society of Clinical Oncology Young Investigator Award, Outstanding Physician Volunteer for the Leukemia Lymphoma Society, Virginia and Cockrell Presidential Scholar at the Houston Methodist, Who's Who in Healthcare, America's Top Physicians, 2007-present, HealthCare Network Excellence Award 2017 and 2022. His work has been supported by grants from American Cancer Society, Leukemia Lymphoma Society, National Institute of Health and several industry partners. He enjoys mentoring high school and college students to gear them towards the next generation of physician scientists. His twitter handle is @Bloodbytes or @DrSwami\_Iyer.

## Dr. Alison Moskowitz

---

Dr. Alison Moskowitz is an Associate Attending within the Lymphoma service at Memorial Sloan Kettering Cancer Center. She earned her medical degree at Albert Einstein College of Medicine, completed an internship and residency in internal medicine at Columbia University Medical Center, and completed fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.



Dr. Moskowitz's research is dedicated to developing new treatment strategies for T-cell lymphoma and relapsed/refractory Hodgkin lymphoma. Her research program in Hodgkin lymphoma focuses on developing novel treatment approaches for patients with relapsed or refractory disease and identifying factors predictive of response to therapy and overall outcomes. The aim of this work is to ultimately develop individualized therapy for patients with Hodgkin lymphoma that optimizes cure and limits longterm toxicity.

For T-cell lymphoma, she aims to develop new agents through clinical trials that incorporate strong correlative studies aimed at identifying markers of sensitivity and resistance. These studies will allow us to design personalized treatment approaches, predict optimal combination strategies, and ultimately improve prognosis by rationally designing regimens that target the diverse T-cell lymphoma entities.



## Dr. Nitin Jain

---

Nitin Jain, M.D., is a Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas, USA.



He earned his medical degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2002. He completed Internal Medicine residency at the Medical College of Wisconsin, Milwaukee. He then completed clinical fellowship in Leukemia at MDACC followed by a Leukemia research fellowship at Memorial Sloan-Kettering Cancer Center. He then pursued fellowship in Hematology/Oncology at The University of Chicago. He joined as a faculty in the Department of Leukemia at MDACC in July 2012. Dr. Jain treats patients with acute and chronic leukemias with focus of patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

Dr. Jain research interests focus on new drug development for patients with leukemia, especially CLL and ALL. Since 2021, he has also served as Director, Leukemia CAR-T Program within the Department of Leukemia, MDACC.

Dr. Jain is Principal Investigator of several investigator-initiated phase I-II clinical trials, including combination targeted therapies (ibrutinib and venetoclax) in CLL, checkpoint inhibitor in Richter transformation, JAK2 inhibitor ruxolitinib in Ph-like ALL, novel CD22 antibody drug conjugate in B-ALL, venetoclax + chemotherapy in B- and T-ALL, ponatinib in T-ALL, and off-the-self allogeneic CARTs in B-ALL. The trial combining ibrutinib and venetoclax was published in New England Journal of Medicine in 2019. He has published papers in prominent journals including NEJM, Lancet, JAMA Oncology, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Leukemia & Lymphoma, and others.

He has won many awards during his career including Sardari Lal Kalra Gold Medal in Microbiology from AIIMS and Merit Award from the American Society of Clinical Oncology (ASCO). He secured first rank at the national level in India in the medical school (AIIMS) entrance examination. He received High-Impact Clinical Research Support Award from MD Anderson Cancer Center in the year 2014

and 2016. He has served as faculty on American Society of Hematology CRTI workshop from 2017–2019. He is recipient of Sabin Family Foundation Award in 2018. In 2020, he received MD Anderson Faculty Scholar award. In 2021, he was appointed Director of the CAR-T program for the Leukemia Department, MDACC.

In 2022, he received Leukemia and Lymphoma Society (LLS) Career Development Program (CDP) Award as well as LLS Translational Research Program (TRP) award.

## Dr. Jennifer Brown

---

Jennifer R. Brown, M.D., Ph.D. is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute (DFCI) and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.



Dr. Brown completed a B.S. and M.S. simultaneously in molecular biophysics and biochemistry (MB&B) at Yale, graduating summa cum laude with distinction. She proceeded to Harvard Medical School where she received her M.D. and Ph.D. in molecular genetics in 1998 and was awarded the James Tolbert Shipley Prize. She then served as an intern and resident in Internal Medicine at Massachusetts General Hospital followed by a fellowship in Hematology and Medical Oncology at DFCI. Dr. Brown joined the faculty of DFCI and Harvard Medical School in 2004, where she has an active clinical-translational research program in CLL.

Her interests include the development of novel targeted therapeutics for CLL, as well as CLL genomics. She has been instrumental in the clinical development of idelalisib, ibrutinib, and zanubrutinib, leading to their regulatory approvals in CLL. Her genomics work has characterized the somatic mutation profile of CLL, and she also has a longstanding research interest in the inherited predisposition to CLL. To date, she has published about 335 papers in the scientific literature, predominantly in CLL. In 2014 she was the recipient of two awards from DFCI, the Clinical Innovation Award, as well as the George Canellos Award. She is a member of the International Workshop on CLL (iwCLL) and Chair of the 20th International Workshop on CLL, held in Boston in 2023. She enjoys a worldwide reputation as a CLL expert having made the Highly Cited Researchers list by Clarivate, with multiple papers ranking in the top 1% by citations for their field and year of publication.

## **Dr. Courtney Dinardo**

---

Dr. DiNardo is an academic clinician with a focus on individualized therapy and precision oncology for myeloid malignancies, including the optimal incorporation of genomics into standard risk assessments and treatment algorithms, and the clinical evaluation of targeted therapeutics for molecularly-defined patient subgroups.



Dr. DiNardo has extensive experience in designing and implementing clinical trials in AML and has served an integral role in several highly influential trials involving IDH1, IDH2 and BCL2 inhibitors, which have led to the FDA approval of three therapies in AML since 2017 (the first-in-class IDH2 inhibitor enasidenib, the IDH1 inhibitor ivosidenib, and the BCL2 inhibitor venetoclax in combination with hypomethylating agents).

## Dr. Gail Roboz

---

Dr. Roboz is an internationally recognized expert in developmental therapeutics and novel clinical trials for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders.



She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts.

Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology co-chairs the clinical committee of the European Leukemia Net (ELN) working group on measurable residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

## Dr. Loretta Nastoupil

---

Loretta J. Nastoupil, MD is an Associate Professor in the Department of Lymphoma/Myeloma at the University of Texas MD Anderson Cancer Center in Houston, TX USA.



Dr. Nastoupil received her medical degree from the University of Texas Southwestern Medical School and completed her internal medicine training at Washington University and hematology/medical oncology fellowship at Emory University. She is currently Deputy Chair of the Lymphoma/Myeloma Department and Section Chief of the indolent lymphoma and new drug development teams which are in line with her research interests of designing and conducting prospective trials aimed at exploiting the immune system to eradicate B-cell lymphoma. She has led phase 1, 2, and 3 trials in follicular and diffuse large B-cell lymphoma. She is also interested in real world evidence and has been involved in exploring outcomes among patients treated with standard of care CAR T cell therapy and generating synthetic control arms for single arm phase 2 studies.



## Dr. Steven Howitz

---

Dr. Steven Horwitz is an Attending Physician in the Department of Medicine at Memorial Hospital for Cancer and Allied Diseases and a Member at Memorial Sloan Kettering Cancer Center in New York City.



He earned his medical degree at Case Western Reserve University School of Medicine, completed an internship and residency in internal medicine at the University of Rochester/Strong Memorial Hospital, and then completed a fellowship in medical oncology at Stanford University Medical Center.

Much of his current research is dedicated to investigating targeted or immunotherapeutic approaches to try to identify better, and often less toxic treatments for individuals with T-cell lymphomas. His research also focuses on better understanding mechanisms of response and resistance to novel drugs in T-cell lymphoma to help provide individualized treatments in the future. Dr. Horwitz participates in several national, and international committees and consortiums dedicated to the understanding and advancement of treatment for T-cell lymphoma. Since 2017 he has been the Chair of the NCCN panel on Guidelines for Treatment of T-Cell/Primary Cutaneous B-Cell Lymphomas.

## **Dr. Lucia Masarova**

---

Dr. Masarova is an Assistant Professor at the MD Anderson Cancer Center in Houston, Texas at the Department of Leukemia with special interest in myeloid malignancies and myeloproliferative neoplasms. Dr. Masarova's broad clinical knowledge in oncology and malignant hematology has been obtained through trainings in Europe and in the USA, where she trained under the mentorship of the leaders in the field. Current research is dominated by myeloproliferative neoplasms. She has published numerous first-authored articles of original research and is principal investigator of clinical trials for myeloproliferative neoplasms.



## **Dr. William G. Wierda**

---

William G. Wierda, MD, PhD, is Professor of Medicine and Medical Director for the Department of Leukemia and Executive Medical Director inpatient medical services at The University of Texas MD Anderson Cancer Center.



Dr. Wierda received his Doctor of Philosophy in microbiology and immunology and his medical degree from the University of Health Sciences/The Chicago Medical School. He subsequently completed an internship and residency in internal medicine at Duke University Medical Center, followed by a fellowship in hematology and medical oncology at the University of California, San Diego.

Dr. Wierda's research focuses on studying immunology and immune function in patients with chronic lymphocytic and developing immune-based therapeutic strategies for patients with hematologic malignancies, particularly CLL. He has served as principal investigator or co-investigator for numerous clinical trials, lectured nationally and internationally, and published extensively on clinical and translational aspects of CLL and drug and treatment development.

Dr. Wierda is an executive member of the International Workshop on CLL and member of the American College of Physicians, the American Society of Hematology, the American Society of Clinical Oncology, the American Association of Immunologists, and the European Society of Hematology.

Dr. Wierda serves as Chair of the NCCN CLL/SLL and Hairy Cell Leukemia Panel, the Value Pathways Task Force Member for the NCCN CLL/SLL/Hairy Cell Leukemia Panel. He also serves as peer reviewer for several journals and is an editorial board member for JNCCN - Journal of the National Comprehensive Cancer Network and a scientific review committee member for the NCCN Oncology Research Program.

# We would like to thank our conference sponsors

## DIAMOND



## PLATINUM

abbvie



## GOLD

